Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.40 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.34 |
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9470766 | 0.95 | KDM4E (0.41) | KDM4EMAPTAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL9471242 | 0.90 | AKR1C3 (0.42) | KDM4EMAPTAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL9179945 | 0.82 | KDM4E (0.55) | KDM4EMAPTHDAC4HSD17B10ALDH1A1 | |
| SCHEMBL9178074 | 0.82 | KDM4E (0.44) | KDM4EMAPTHDAC4HSD17B10ALDH1A1 | |
| SCHEMBL9175444 | 0.81 | KDM4E (0.43) | KDM4EMAPTHDAC4HSD17B10ALDH1A1 | |
| SCHEMBL3949652 | 0.81 | KDM4E (0.43) | KDM4EMAPTHDAC4HSD17B10ALDH1A1 | |
| SCHEMBL3950860 | 0.81 | KDM4E (0.43) | KDM4EMAPTAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL3945745 | 0.81 | KDM4E (0.43) | KDM4EMAPTHDAC4HSD17B10ALDH1A1 | |
| SCHEMBL9175188 | 0.78 | NNMT (0.51) | KDM4EMAPTHDAC4HSD17B10ALDH1A1 | |
| SCHEMBL9174721 | 0.78 | XDH (0.45) | KDM4EMAPTHDAC4HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2009-07-02 | — | — | US | claimed |
| EP-2049493-A2 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | Cadila Healthcare Limited (IN) | 2009-04-22 | — | — | EP | claimed |
| WO-2008059513-A2 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2008-05-22 | — | — | WO | claimed |
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2009-07-02 | — | — | US | disclosed |
| EP-0310096-B1 | Novel cyclic anthranilic acid derivatives and process for their preparation | KYORIN SEIYAKU KK (JP) | 1995-04-19 | — | — | EP | disclosed |
| US-5281600-A | Antiinflammatory agents, rheumatic diseases and immunomodulators | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1994-01-25 | — | — | US | disclosed |
| US-5147874-A | Antiarthritic agents | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1992-09-15 | — | — | US | disclosed |
| US-4956372-A | ANTIRHEUMATOID AND IMMUNOMODULATORS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1990-09-11 | — | — | US | disclosed |
| EP-0310096-A2 | Novel cyclic anthranilic acid derivatives and process for their preparation | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CETP, APOB, HDLBP | KDM4E 4055/4885MAPT 144/4885AKR1C3 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.